Research Article

Responsiveness of the Spanish Version of the “Skin Cancer Index”

M. de Troya-Martín,^{1,2} F. Rivas-Ruiz,^{2,3} N. Blázquez-Sánchez,^{1,2}
I. Fernández-Canedo,¹ M. Aguilar-Bernier,¹ J. B. Repiso-Jiménez,¹ J. C. Toribio-Montero,¹
M. Jones-Caballero,⁴ and J. Rhee⁵

¹Department of Dermatology, Agencia Sanitaria Costa del Sol, Marbella, Spain

²Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Spain

³Unit of Investigation, Agencia Sanitaria Costa del Sol, Marbella, Spain

⁴Department of Dermatology, University of Sydney, Sydney, NSW, Australia

⁵Department of Otolaryngology and Communication, Sciences Medical College of Wisconsin, Milwaukee, WI, USA

Correspondence should be addressed to M. de Troya-Martín; magdalenatroya@gmail.com

Received 29 July 2016; Accepted 7 September 2016

Academic Editor: Günther Hofbauer

Copyright © 2016 M. de Troya-Martín et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Skin Cancer Index (SCI) is a specific questionnaire measuring health related quality of life (HRQL) in patients with cervicofacial non-melanoma skin cancer (CFNMSC). The original scale has recently been adapted and validated into Spanish. **Objectives.** Evaluate the responsiveness of the Spanish version of SCI. **Methods.** Patients with CFNMSC candidate for surgical treatment were administered the questionnaire at time of diagnostic (t_0), 7 days after surgery (t_1), and 5 months after surgery (t_2). The scale and subscales scores (C1: social/appearance, C2: emotional) were then evaluated. Differences between t_0 - t_1 , t_1 - t_2 , and t_0 - t_2 were determined and a gender-and-age segmented analysis was performed. **Results.** 88 patients, 54.8% male, mean age 62.5 years, completed the study. Differences between t_0 - t_1 and t_1 - t_2 scores were statistically significant ($p < 0.05$). The lowest values were found at time of diagnosis and postsurgery. Women and patients under 65 years showed the lowest values at the three times. **Limitations.** Concrete geographic and cultural area. Clinical and histological variables are not analysed. **Conclusions.** Our results confirm responsiveness of the Spanish version of the SCI. Further development of the instrument in Spanish-speaking countries and populations will make it possible to extend worldwide research and knowledge horizons on skin cancer.

1. Introduction

Non-melanoma skin cancer (NMSC), basal cell carcinoma (BCC), and squamous cell carcinoma (SCC) are the most common malignant tumours among humans [1, 2]. Their incidence has increased dramatically over the past 20 years, especially among women and people aged 30–39 years [3, 4], as a result of excessive exposure to ultraviolet radiation [5]. Although NMSC has a low mortality rate (0.1–0.3%), its morbidity is high; in over 80% of cases it is located in the face, where the tumour itself or surgical treatment often causes functional and aesthetic problems of diverse types [6, 7]. In addition, there is an accumulated risk of around 40% of developing a second NMSC within three years [8], making this

tumour a chronic and mutilating disease [9]. Health related quality of life (HRQL) is a measure of particular interest with respect to cervicofacial NMSC (CFNMSC). However, the lack of specific instruments and the low sensitivity of the questionnaires previously used have hampered understanding of this essential aspect of the disease, producing results that are sometimes confusing [10–21].

In 2005, Rhee et al. created the first specific HRQL questionnaire for patients with CFNMSC, termed the Skin Cancer Index (SCI), consisting of 15 items exploring three dimensions about HRQL in these patients (emotional, social, and appearance) [22]. In further studies the instrument demonstrated excellent psychometric properties (validity, reliability, and responsiveness) [23, 24]. The Spanish version

of SCI has recently been developed, showing also an excellent level of internal consistency and an adequate level of reliability [25]. The aim of the present study is to assess responsiveness of the Spanish scale.

2. Material and Methods

A prospectively longitudinal study was designed and approved by the Bioethics Committee of our hospital.

Patients were selected consecutively among subjects diagnosed with CFNMSC candidate for surgical treatment at the Dermatology Service of the Costa del Sol Hospital during the period April 2009 to November 2011. All patients included in the study were new-onset patients with CFCCNM confirmed by biopsy (BCC or SCC), aged over 18 years, that correctly understand spoken and written Spanish, and who gave their informed consent to participate. Those who presented intellectual impairment or suffered a severe physical or mental illness were excluded.

The participants were invited to complete the quality-of-life questionnaire at three different time points during the surgical process: t_0 (time of diagnostic confirmation), t_1 (7 days after surgery), and t_2 (5 months after surgery). The Spanish version of the SCI [25] is linguistically and semantically equivalent to the original scale but differs in the number of items, because during the validation process three items were dismissed by not meeting criteria of validity. The final version is composed of 12 items, with two underlying dimensions which we termed (following the original model) “social/appearance” (7 items) and “emotional” (5 items). Both components presented an excellent level of internal consistency, with Cronbach’s alpha values above 0.85. In addition, the Spanish scale provided an adequate level of reliability, with weighted kappa values greater than 0.4 and percentages of absolute agreement exceeding 60% in most items. As the original version, the answers are given on a Likert 5-point scale. The standardised final score ranges from 0 (lowest quality of life) to 100 (highest quality of life).

Responsiveness was assessed as the difference in the mean score in the scale at stages t_0 , t_1 , and t_2 . Second outcome measure might be described as differences in the mean score in age (> or <65 y-o) and sex (male, female) groups.

2.1. Statistical Analysis. The global scores on the scale and its components were obtained at each of the three time points. To assess the sensitivity to change of the instrument, the paired Student’s t -test was used (or the Mann-Whitney test if the criteria for parametric testing were not met). We recorded the differences of the means (DM) of the scores for the scale and its components and the corresponding 95% confidence intervals (95% CI). In addition, an age-and-gender segmented analysis was performed. The level of significance was set at $p < 0.05$. The statistical analysis was carried out using SPSS v15.

3. Results

88 of the 100 patients included in the study completed the survey at all three time points. Of these respondents, 54.8%

TABLE 1: Scale results for all patients assessed ($n = 88$).

	t_0		t_1		t_2	
	Mean	SD	Mean	SD	Mean	SD
Total	59.2	21.2	63.9	20.2	75.3	20.2
C1	79.4	24.8	84.4	23.4	90.5	19.5
C2	31.0	27.0	35.1	28.0	54.1	31.5

TABLE 2: Sensitivity to change.

	Mean	95% confidence interval		p
		Lower	Upper	
<i>Total for the Scale</i>				
Difference t_0-t_1	4.66	1.32	8.01	0.007
Difference t_0-t_2	16.10	12.08	20.12	<0.001
Difference t_1-t_2	11.43	8.05	14.81	<0.001
<i>Component 1</i>				
Difference t_0-t_1	3.98	0.78	7.18	0.015
Difference t_0-t_2	8.86	5.47	12.26	<0.001
Difference t_1-t_2	4.84	2.41	7.26	<0.001
<i>Component 2</i>				
Difference t_0-t_1	3.42	-0.73	7.56	0.105
Difference t_0-t_2	18.50	13.29	23.71	<0.001
Difference t_1-t_2	15.18	10.11	20.25	<0.001

were men, with a mean age of 62.5 years (SD: 14.1). On a standardized scale 0–100, the mean total scores were 59.2 (t_0), 63.9 (t_1), and 75.3 (t_2). The mean scores for the CI scale component were 79.4 (t_0), 84.4 (t_1), and 90.5 (t_2), and those for the C2 component were 31.0 (t_0), 35.1 (t_1), and 54.1 (t_2) (Table 1).

The differences in the total score for the scale, in all the pairwise comparisons, were statistically significant: t_0 versus t_1 (DM: 2.24; 95% CI 0.63–3.84), t_0 versus t_2 (DM: 7.73; 95% CI 5.80–9.66), and t_1 versus t_2 (DM: 5.49; 95% CI 3.86–7.11), except for t_0-t_1 in C2 (Table 2).

In the gender-and age segmented analysis, women and subjects younger than 65 years had lower scores at all three time points, and the changes over time were statistically significant in all tests for t_0-t_2 and t_1-t_2 , except for t_1-t_2 in C1 in the subjects aged over 65 years (Tables 3 and 4).

4. Discussion

Responsiveness, defined as “the ability of an instrument to detect change over time in the construct to be measured,” is the third main psychometric property, together with validity and reliability, to consider in health related questionnaires [26, 27].

Our results confirm responsiveness of the Spanish version of the SCI. We have used the same methodology the authors did to test responsiveness of the original questionnaire [16], following the recommendations of the international guidelines for validating health questionnaires [26–28]. Our study has been carried out in patients with CFNMSC undergoing surgery at three different time points of the medical care process. For the overall scale and the subscales, the capacity

TABLE 3: Scale results, segmented by sex ($n = 88$).

	t_0		t_1		t_2		$p_{t_0-t_1}$	$p_{t_0-t_2}$	$p_{t_1-t_2}$
	Mean	SD	Mean	SD	Mean	SD			
Total									
Male	61.6	22.5	65.2	20.8	78.9	20.5	0.073	<0.001	<0.001
Female	57.4	19.1	62.9	19.3	70.6	20.0	0.081	<0.001	0.005
C1									
Male	82.8	24.0	86.8	22.2	92.3	18.2	0.021	<0.001	0.007
Female	76.3	25.1	82.5	24.9	88.3	21.8	0.15	0.005	0.029
C2									
Male	32.1	30.2	35.0	30.5	60.1	32.4	0.425	<0.001	<0.001
Female	30.9	23.7	35.5	25.2	45.8	29.7	0.278	0.002	0.014

TABLE 4: Scale results, segmented by age ($n = 88$).

	t_0		t_1		t_2		$p_{t_0-t_1}$	$p_{t_0-t_2}$	$p_{t_1-t_2}$
	Mean	SD	Mean	SD	Mean	SD			
Total									
<65	55.0	20.0	58.7	19.5	70.7	20.0	0.166	<0.001	<0.001
≥65	62.6	21.6	68.3	19.8	79.3	19.7	0.014	<0.001	<0.001
C1									
<65	75.8	26.2	79.2	24.7	88.0	20.8	0.293	0.001	0.001
≥65	82.4	23.3	89.2	21.3	92.6	18.3	0.015	<0.001	0.08
C2									
<65	25.9	21.5	30.1	25.5	46.5	30.8	0.241	<0.001	0.001
≥65	35.0	30.7	39.1	29.5	60.7	30.7	0.316	<0.001	<0.001

of the instrument to identify changes in the subjects' HRQL has been revealed.

Like similar studies in the USA, the UK, or Canada [16, 29–31], patients with CFNMSC experienced a significant impact on their HRQL at the moment of diagnosis, and surgical treatment produces a marked improvement, as indicated by the significant increase in the scale score. HRQL was found to be more severely affected among female patients and patients of both sexes aged under 65 years, as reported by Rhee et al. [16]. Unlike other studies conducted in Anglo-Saxon countries [16, 29, 30], the values for emotional subscale were considerably lower than those for the social-appearance component, for all time points and all groups of patients.

As this is the only version of the scale measuring HRQL in patients with NMSC developed in a language other than the original, its implementation in countries and populations belonging to a Spanish-language culture will make it possible to extend worldwide research horizons of the disease.

This is a single-center study conducted in a particular sociocultural context. Therefore, our data need to be confirmed, by extending this investigation to other areas of Spain and to Latin American countries.

In conclusion, our results confirm the ability of the Spanish version of the SCI to discriminate changes in the HRQL of patients with CFNMSC. In the future, its implementation in Spanish-speaking countries and populations will make it possible to extend worldwide research on skin cancer.

Abbreviations

NMSC:	Non-melanoma skin cancer
BCC:	Basal cell carcinoma
SCC:	Squamous cell carcinoma
CFNMSC:	Cervicofacial non-melanoma skin cancer
SCI:	Skin Cancer Index
HRQL:	Health related quality of life.

Disclosure

For this type of study, formal consent is not required.

Competing Interests

The authors declare that they have no conflict of interests.

Acknowledgments

This study was funded by Health Ministry of Andalusia (Grant no. PI-0093/2008).

References

- [1] B. Ö. Cakir, P. Adamson, and C. Cingi, "Epidemiology and economic burden of nonmelanoma skin cancer," *Facial Plastic Surgery Clinics of North America*, vol. 20, no. 4, pp. 419–422, 2012.
- [2] A. Lomas, J. Leonardi-Bee, and F. Bath-Hextall, "A systematic review of worldwide incidence of nonmelanoma skin cancer,"

- British Journal of Dermatology*, vol. 166, no. 5, pp. 1069–1080, 2012.
- [3] P. Aceituno-Madera, A. Buendía-Eisman, S. Arias-Santiago, and S. Serrano-Ortega, “Evolución de la incidencia del cáncer de piel en el período 1978–2002,” *Actas Dermo-Sifiliográficas*, vol. 101, no. 1, pp. 39–46, 2010.
 - [4] S. C. Flohil, I. Seubring, M. M. van Rossum, J.-W. W. Coebergh, E. de Vries, and T. Nijsten, “Trends in basal cell carcinoma incidence rates: a 37-year dutch observational study,” *Journal of Investigative Dermatology*, vol. 133, no. 4, pp. 913–918, 2013.
 - [5] V. Molho-Pessach and M. Lotem, “Ultraviolet radiation and cutaneous carcinogenesis,” *Current Problems in Dermatology*, vol. 35, pp. 14–27, 2007.
 - [6] T. H. Nguyen and D. Q.-D. Ho, “Nonmelanoma skin cancer,” *Current Treatment Options in Oncology*, vol. 3, no. 3, pp. 193–203, 2002.
 - [7] V. Madan, J. T. Lear, and R.-M. Szeimies, “Non-melanoma skin cancer,” *The Lancet*, vol. 375, no. 9715, pp. 673–685, 2010.
 - [8] N. Roberts, Z. Czajkowska, G. Radiotis, and A. Körner, “Distress and coping strategies among patients with skin cancer,” *Journal of Clinical Psychology in Medical Settings*, vol. 20, no. 2, pp. 209–214, 2013.
 - [9] S. van der Geer, H. A. Reijers, H. F. J. M. van Tuijl, H. de Vries, and G. A. M. Krekels, “Need for a new skin cancer management strategy,” *Archives of Dermatology*, vol. 146, no. 3, pp. 332–336, 2010.
 - [10] S. Blackford, D. Roberts, M. S. Salek, and A. Finlay, “Basal cell carcinomas cause little handicap,” *Quality of Life Research*, vol. 5, no. 2, pp. 191–194, 1996.
 - [11] R. E. Davis and J. M. Spercer, “Basal and squamous cell cancer of the facial skin,” *Current Opinion in Otolaryngology & Head and Neck Surgery*, vol. 5, pp. 86–92, 1997.
 - [12] J. S. Rhee, F. R. Loberiza, B. A. Matthews, M. Neuburg, T. L. Smith, and M. Burzynski, “Quality of life assessment in non-melanoma cervicofacial skin cancer,” *Laryngoscope*, vol. 113, no. 2, pp. 215–220, 2003.
 - [13] J. S. Rhee, B. A. Matthews, M. Neuburg, T. L. Smith, M. Burzynski, and A. B. Nattinger, “Skin cancer and quality of life: assessment with the dermatology life quality index,” *Dermatologic Surgery*, vol. 30, no. 4, pp. 525–529, 2004.
 - [14] J. S. Rhee, B. A. Matthews, M. Neuburg, T. L. Smith, M. Burzynski, and A. B. Nattinger, “Quality of life and sun-protective behavior in patients with skin cancer,” *Archives of Otolaryngology—Head and Neck Surgery*, vol. 130, no. 2, pp. 141–146, 2004.
 - [15] F. J. Moloney, S. Keane, P. O’Kelly, P. J. Conlon, and G. M. Murphy, “The impact of skin disease following renal transplantation on quality of life,” *British Journal of Dermatology*, vol. 153, no. 3, pp. 574–578, 2005.
 - [16] J. S. Rhee, B. A. Matthews, M. Neuburg, B. R. Logan, M. Burzynski, and A. B. Nattinger, “The skin cancer index: clinical responsiveness and predictors of quality of life,” *Laryngoscope*, vol. 117, no. 3, pp. 399–405, 2007.
 - [17] T. Chen, D. Bertenthal, A. Sahay, S. Sen, and M.-M. Chren, “Predictors of skin-related quality of life after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma,” *Archives of Dermatology*, vol. 143, no. 11, pp. 1386–1392, 2007.
 - [18] M.-M. Chren, A. P. Sahay, D. S. Bertenthal, S. Sen, and C. S. Landefeld, “Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma,” *Journal of Investigative Dermatology*, vol. 127, no. 6, pp. 1351–1357, 2007.
 - [19] J. Steinbauer, M. Koller, E. Kohl, S. Karrer, M. Landthaler, and R.-M. Szeimies, “Quality of life in health care of non-melanoma skin cancer—results of a pilot study,” *Journal of the German Society of Dermatology*, vol. 9, no. 2, pp. 129–135, 2011.
 - [20] M.-M. Chren, “The Skindex instruments to measure the effects of skin disease on quality of life,” *Dermatologic Clinics*, vol. 30, no. 2, pp. 231–236, 2012.
 - [21] F. Sampogna, A. Spagnoli, C. Di Pietro et al., “Field performance of the skindex-17 quality of life questionnaire: a comparison with the skindex-29 in a large sample of dermatological outpatients,” *Journal of Investigative Dermatology*, vol. 133, no. 1, pp. 104–109, 2013.
 - [22] J. S. Rhee, B. A. Matthews, M. Neuburg, M. Burzynski, and A. B. Nattinger, “Creation of a quality of life instrument for non-melanoma skin cancer patients,” *Laryngoscope*, vol. 115, no. 7, pp. 1178–1185, 2005.
 - [23] J. S. Rhee, B. A. Matthews, M. Neuburg, B. R. Logan, M. Burzynski, and A. B. Nattinger, “Validation of a quality-of-life instrument for patients with nonmelanoma skin cancer,” *Archives of Facial Plastic Surgery*, vol. 8, no. 5, pp. 314–318, 2006.
 - [24] B. A. Matthews, J. S. Rhee, M. Neuburg, M. L. Burzynski, and A. B. Nattinger, “Development of the facial skin care index: a health-related outcomes index for skin cancer patients,” *Dermatologic Surgery*, vol. 32, no. 7, pp. 924–934, 2006.
 - [25] M. de Troya-Martín, F. Rivas-Ruiz, N. Blázquez-Sánchez et al., “A Spanish version of the skin cancer index: a questionnaire for measuring quality of life in patients with cervicofacial non-melanoma skin cancer,” *British Journal of Dermatology*, vol. 172, no. 1, pp. 160–168, 2015.
 - [26] X. Badia, M. Salamero, and J. Alonso, *La Medida de la Salud. Guía de Escalas de Medición en Español*, Fundación Lilly, Barcelona, Spain, 3rd edition, 2002.
 - [27] A. Carvajal, C. Centeno, R. Watson et al., “How is an instrument for measuring health to be validated?” *Anales del Sistema Sanitario de Navarra*, vol. 34, pp. 63–72, 2011.
 - [28] J. M. Ramada-Rodilla, C. Serra-Pujadas, and G. L. Delclós-Clanchet, “Cross-cultural adaptation and health questionnaires validation: revision and methodological recommendations,” *Salud Pública de México*, vol. 55, no. 1, pp. 57–66, 2013.
 - [29] J. Caddick, L. Green, J. Stephenson, and G. Spyrou, “The psycho-social impact of facial skin cancers,” *Journal of Plastic, Reconstructive and Aesthetic Surgery*, vol. 65, no. 9, pp. e257–e259, 2012.
 - [30] G. Radiotis, N. Roberts, Z. Czajkowska, M. Khanna, and A. Körner, “Nonmelanoma skin cancer: disease-specific quality-of-life concerns and distress,” *Oncology Nursing Forum*, vol. 41, no. 1, pp. 57–65, 2014.
 - [31] P. C. Maciel, F. E. M. Fonseca, J. Veiga-Filho, L. M. Ferreira, M. P. de Carvalho, and D. F. Veiga, “Quality of life and self-esteem in patients submitted to surgical treatment of skin carcinomas: long-term results,” *Anais Brasileiros de Dermatologia*, vol. 89, no. 4, pp. 594–598, 2014.